Pertuzumab in neoadjuvant treatment of HER2-positive early breast cancer

Journal of Community and Supportive Oncology

Volumn 12, Issue 3, 2014, Pages 84-86

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; PERTUZUMAB; TRASTUZUMAB;

ADULT; ALOPECIA; ANAPHYLAXIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERSENSITIVITY; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEOADJUVANT THERAPY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); THROMBOCYTOPENIA;

EID: 84991650697     PISSN: 23307749     EISSN: None     Source Type: Journal    
DOI: 10.12788/jcso.0023     Document Type: Article

References (4)

1. US Food and Drug Administration. Pertuzumab injection. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm370449.htm. Released September 30, 2013. Accessed February 25, 2014.
2. Perjeta [package insert]. San Francisco, CA: Genentech Inc; 2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125409s051lbl.pdf. Accessed February 25, 2014.
3. Gianni L, Pienkowski T, Im YH, et al. Efcacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, infammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012:13:25-32.
4. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278-2284.